Abstract
The development of T cell-based immunotherapies of cancer depends on the identification of tumor-associated antigens capable of eliciting tumor-directed cytotoxic T cell responses. In malignant glioma the number of well-defined target antigens for cytotoxic T lymphocytes (CTLs) is still very limited. Recently, we demonstrated the abundant and specific overexpression of the transcription factor SOX11 in malignant glioma. Here, we describe the SOX11-derived peptide LLRRYNVAKV which is capable of inducing human leukocyte antigen-A*0201-restricted and tumor-reactive CTLs. This novel CTL epitope may serve as an attractive candidate for a T cell-based immunotherapy of glioma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
CD8-Positive T-Lymphocytes / cytology
-
CD8-Positive T-Lymphocytes / immunology
-
Cell Line, Tumor
-
Cytotoxicity, Immunologic
-
Epitopes, T-Lymphocyte / chemistry
-
Epitopes, T-Lymphocyte / immunology*
-
Glioma / immunology*
-
Glioma / pathology
-
HLA-A Antigens / immunology
-
HLA-A2 Antigen
-
High Mobility Group Proteins / chemistry
-
High Mobility Group Proteins / immunology*
-
Humans
-
K562 Cells
-
Molecular Weight
-
Oligopeptides / chemistry
-
Oligopeptides / immunology
-
SOXC Transcription Factors
Substances
-
Epitopes, T-Lymphocyte
-
HLA-A Antigens
-
HLA-A*02:01 antigen
-
HLA-A2 Antigen
-
High Mobility Group Proteins
-
Oligopeptides
-
SOX11 protein, human
-
SOXC Transcription Factors